Goldman Sachs Forecast, price target & analysts
Goldman Sachs Target price 2025 - Analyst rating & recommendation
Goldman Sachs Classifications & Recommendation:
Goldman Sachs Price Target
| Target Price | $597.72 |
| Price | $707.75 |
| Deviation | 15.55% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target Goldman Sachs 2026 . The average Goldman Sachs target price is $597.72. This is 15.55% lower than the current stock price. The highest price target is $756.00 6.82% , the lowest is $505.00 28.65% . | |
| A rating was issued by 30 analysts: 17 Analysts recommend Goldman Sachs to buy, 13 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Goldman Sachs stock has an average upside potential 2026 of 15.55% . Most analysts recommend the Goldman Sachs stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
26 Analysts have issued a sales forecast Goldman Sachs 2025 . The average Goldman Sachs sales estimate is $57.1b . This is 54.76% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $60.7b 51.92% , the lowest is $52.5b 58.45% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $127b | 17.00% |
|---|---|---|
| 2025 | $57.1b | 54.98% |
| 2026 | $59.2b | 3.64% |
| 2027 | $60.6b | 2.30% |
| 2028 | $59.7b | 1.41% |
| 2029 | $63.5b | 6.38% |
| 2030 | $64.6b | 1.74% |
| 2031 | $68.3b | 5.67% |
| 2032 | $70.4b | 3.18% |
4 Analysts have issued an Goldman Sachs EBITDA forecast 2025. The average Goldman Sachs EBITDA estimate is $19.1b . This is 9.18% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $19.5b 7.41% , the lowest is $18.2b 13.59% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $20.9b | 29.37% |
|---|---|---|
| 2025 | $19.1b | 8.23% |
| 2026 | $20.9b | 8.99% |
EBITDA Margin
| 2024 | 16.44% | 10.57% |
|---|---|---|
| 2025 | 33.52% | 103.84% |
| 2026 | 35.25% | 5.16% |
29 Goldman Sachs Analysts have issued a net profit forecast 2025. The average Goldman Sachs net profit estimate is $14.4b . This is 1.42% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $15.6b 9.91% , the lowest is $13.0b 8.57% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $13.5b | 71.05% |
|---|---|---|
| 2025 | $14.4b | 6.31% |
| 2026 | $15.9b | 10.61% |
| 2027 | $17.4b | 9.21% |
| 2028 | $15.1b | 12.81% |
| 2029 | $16.5b | 9.11% |
| 2030 | $17.2b | 4.34% |
| 2031 | $18.5b | 7.41% |
| 2032 | $18.7b | 0.97% |
Net Margin
| 2024 | 10.66% | 46.19% |
|---|---|---|
| 2025 | 25.18% | 136.17% |
| 2026 | 26.87% | 6.71% |
| 2027 | 28.69% | 6.77% |
| 2028 | 25.37% | 11.57% |
| 2029 | 26.02% | 2.56% |
| 2030 | 26.69% | 2.57% |
| 2031 | 27.12% | 1.61% |
| 2032 | 26.54% | 2.14% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
29 Analysts have issued a Goldman Sachs forecast for earnings per share. The average Goldman Sachs EPS is $46.27 . This is 5.93% higher than earnings per share in the financial year 2024. The highest EPS forecast is $50.14 14.79% , the lowest is $41.71 4.51% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $40.54 | 77.26% |
|---|---|---|
| 2025 | $46.27 | 14.13% |
| 2026 | $51.18 | 10.61% |
| 2027 | $55.89 | 9.20% |
| 2028 | $48.73 | 12.81% |
| 2029 | $53.17 | 9.11% |
| 2030 | $55.48 | 4.34% |
| 2031 | $59.59 | 7.41% |
| 2032 | $60.16 | 0.96% |
P/E ratio
| Current | 15.82 | 9.47% |
|---|---|---|
| 2025 | 14.93 | 5.60% |
| 2026 | 13.50 | 9.58% |
| 2027 | 12.36 | 8.44% |
| 2028 | 14.18 | 14.72% |
| 2029 | 12.99 | 8.39% |
| 2030 | 12.45 | 4.16% |
| 2031 | 11.59 | 6.91% |
| 2032 | 11.48 | 0.95% |
Based on analysts' sales estimates for 2025, the Goldman Sachs stock is valued at an EV/Sales of 20.66 and an P/S ratio of 3.71 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 9.35 | 3.77% |
|---|---|---|
| 2025 | 20.66 | 120.97% |
| 2026 | 19.93 | 3.51% |
| 2027 | 19.49 | 2.24% |
| 2028 | 19.77 | 1.43% |
| 2029 | 18.58 | 6.00% |
| 2030 | 18.26 | 1.71% |
| 2031 | 17.28 | 5.37% |
| 2032 | 16.75 | 3.08% |
P/S ratio
| Current | 1.68 | 33.24% |
|---|---|---|
| 2025 | 3.71 | 121.04% |
| 2026 | 3.58 | 3.51% |
| 2027 | 3.50 | 2.25% |
| 2028 | 3.55 | 1.43% |
| 2029 | 3.34 | 6.00% |
| 2030 | 3.28 | 1.71% |
| 2031 | 3.10 | 5.37% |
| 2032 | 3.01 | 3.08% |
Current Goldman Sachs Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jun 23 2025 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Apr 15 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Apr 15 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Apr 15 2025 |
| JMP Securities |
Market Outperform
➜
Market Outperform
|
Unchanged | Apr 08 2025 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Apr 03 2025 |
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Apr 01 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jun 23 2025 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Apr 15 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Apr 15 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Apr 15 2025 |
|
Unchanged
JMP Securities:
Market Outperform
➜
Market Outperform
|
Apr 08 2025 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Apr 03 2025 |
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Apr 01 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
